Recently, with the release of the first "Chinese Clinical Practice Guidelines for Hypertension", the new guidelines recommend that the diagnostic threshold of hypertension in adults in China be lowered from ≥140/90mmHg to ≥130/80mmHg
.
This adjustment quickly made the topic of "high blood pressure" hot
.
According to statistics, after the diagnostic criteria are lowered, 300 million new hypertensive patients
will be added.
With the expansion of the drug group, it may drive the growth
of the antihypertensive drug market.
However, from the perspective of industry analysis, the antihypertensive drug market will not be greatly affected, because on the one hand, the new 300 million hypertensive patients do not necessarily need to take medicine, and second, under the centralized procurement and price reduction, the opportunity for antihypertensive drugs to be administered to companies to make money is very small
.
Valsartan reduced to 0.
1 yuan per tablet, how should pharmaceutical companies cope with the challenge of cost reduction and cost control? (Image source: Pharma Network)
Taking the commonly used antihypertensive drug valsartan as an example, after centralized procurement, valsartan has been as low as 0.
1 yuan per tablet, and the price of such a low price sales, pharmaceutical companies can obtain significantly thin profits
.
However, valsartan has become an internationally recognized first-line antihypertensive treatment drug due to its advantages of stable blood pressure reduction, good effect and good safety, and the market demand is huge
.
In China, according to the statistics of the health department in 2022, the number of hypertension in China has reached 245 million, and the market demand for valsartan is also relatively strong
.
According to data from Minai.
com, in 2020, the sales of valsartan in China's urban public hospitals, county-level public hospitals, urban community centers, township health centers and China's urban physical pharmacy terminals have exceeded 5 billion yuan
.
For valsartan manufacturers, a major challenge is how to deal with cost reduction and cost
control under the general trend of centralized procurement and price reduction.
It is understood that valsartan has some technical difficulties, such as insoluble in water, easy to absorb moisture and become sticky, which brings certain difficulties
to the preparation process.
At present, the pharmaceutical factory producing valsartan oral dosage form mainly adopts two process methods: wet granulation and dry granulation, in which wet granulation needs to be combined with excipients, but there are defects of long preparation time and high cost, dry granulation does not need to add auxiliary materials, and has the advantages of
high efficiency and low cost.
In contrast, dry granulation is a formulation process that can help the production
of high-purity valsartan.
However, at present, the performance stability of the domestic dry granulator needs to be improved, because valsartan is more sensitive to temperature and pressure, the conventional dry granulator in the continuous production process, if the temperature and pressure control is improper, it will affect the quality of valsartan product quality, and even cause material waste
.
It can be seen that in order to help the stable production of valsartan, dry granulator manufacturers need to continuously increase research and development to improve the stability of equipment, so as to ensure the consistency of product production and achieve the purpose of
reducing costs and increasing efficiency.
It is reported that Canaan Technology in order to solve this bottleneck has newly developed LGX series dry granulator, which adopts a newly designed intelligent temperature control system and PID adjustment pressure control system, which can better control temperature and pressure, ensure the high efficiency and stability of high-purity valsartan preparation, make the product compactness, consistency and granulation better, and effectively avoid crystal seizure
.
In addition, the equipment also adopts a unique conveyor screw treatment process, which increases wear resistance and is easier to clean
.
The comparative test results show that the production using conventional dry machine has different degrees of cleanliness, and the isomer content is close to 1.
5%.
However, the valsartan produced by LGX series dry granulator has only 0.
70% sample isomer content sampled from the surface of the conveying screw and the conveying shell after the granulation is completed
.
epilogue
The number of hypertensive patients in China is huge, the prevalence is still increasing, and the demand for antihypertensive drugs is still huge
.
At present, the antihypertensive drug market has become saturated, and the centralized procurement and price reduction has brought cost pressure to antihypertensive drug manufacturers, in this context, the pressure of pharmaceutical manufacturers may be transmitted to the upstream pharmaceutical equipment industry, forcing pharmaceutical machine companies to develop
in a more intelligent and automated direction.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
